342 related articles for article (PubMed ID: 33149670)
1. Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options.
Gampenrieder SP; Castagnaviz V; Rinnerthaler G; Greil R
Cancer Manag Res; 2020; 12():10615-10629. PubMed ID: 33149670
[TBL] [Abstract][Full Text] [Related]
2. Margetuximab and trastuzumab deruxtecan: New generation of anti-HER2 immunotherapeutic agents for breast cancer.
Nur Husna SM; Wong KK
Mol Immunol; 2022 Dec; 152():45-54. PubMed ID: 36272249
[TBL] [Abstract][Full Text] [Related]
3. Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF; Bruni S; Mauro FL; Schillaci R
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046648
[TBL] [Abstract][Full Text] [Related]
4. Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies.
Tapia M; Hernando C; Martínez MT; Burgués O; Tebar-Sánchez C; Lameirinhas A; Ágreda-Roca A; Torres-Ruiz S; Garrido-Cano I; Lluch A; Bermejo B; Eroles P
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760491
[TBL] [Abstract][Full Text] [Related]
5. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
6. Margetuximab for the treatment of HER2-positive metastatic breast cancer.
Tarantino P; Morganti S; Uliano J; Giugliano F; Crimini E; Curigliano G
Expert Opin Biol Ther; 2021 Feb; 21(2):127-133. PubMed ID: 33238772
[TBL] [Abstract][Full Text] [Related]
7. ASCO 2018: highlights in HER2-positive metastatic breast cancer.
Bartsch R; Bergen E
Memo; 2018; 11(4):280-283. PubMed ID: 30595754
[TBL] [Abstract][Full Text] [Related]
8. Recent advances in novel targeted therapies for HER2-positive breast cancer.
Murphy CG; Morris PG
Anticancer Drugs; 2012 Sep; 23(8):765-76. PubMed ID: 22824822
[TBL] [Abstract][Full Text] [Related]
9. HER2-Positive Metastatic Breast Cancer: Available Treatments and Current Developments.
Essadi I; Benbrahim Z; Kaakoua M; Reverdy T; Corbaux P; Freyer G
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980624
[TBL] [Abstract][Full Text] [Related]
10. Clinical development and current role of margetuximab for the treatment of breast cancer.
Tarantino P; Uliano J; Morganti S; Giugliano F; Crimini E; Curigliano G
Drugs Today (Barc); 2021 Sep; 57(9):551-558. PubMed ID: 34586103
[TBL] [Abstract][Full Text] [Related]
11. Treating Advanced Unresectable or Metastatic HER2-Positive Breast Cancer: A Spotlight on Tucatinib.
Ulrich L; Okines AFC
Breast Cancer (Dove Med Press); 2021; 13():361-381. PubMed ID: 34079368
[TBL] [Abstract][Full Text] [Related]
12. Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer.
Singh DD; Lee HJ; Yadav DK
Front Pharmacol; 2022; 13():1089066. PubMed ID: 36578543
[TBL] [Abstract][Full Text] [Related]
13. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
14. Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.
Brandão M; Pondé NF; Poggio F; Kotecki N; Salis M; Lambertini M; de Azambuja E
Expert Rev Anticancer Ther; 2018 Jul; 18(7):629-649. PubMed ID: 29781317
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
Wong DJ; Hurvitz SA
Ann Transl Med; 2014 Dec; 2(12):122. PubMed ID: 25568875
[TBL] [Abstract][Full Text] [Related]
16. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.
Tarantino P; Morganti S; Curigliano G
Explor Target Antitumor Ther; 2021; 2(2):139-155. PubMed ID: 36046143
[TBL] [Abstract][Full Text] [Related]
17. The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates.
Escrivá-de-Romaní S; Saura C
Cancer Drug Resist; 2023; 6(1):45-58. PubMed ID: 37065870
[TBL] [Abstract][Full Text] [Related]
18. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
19. Standard-of-Care Treatment for HER2+ Metastatic Breast Cancer and Emerging Therapeutic Options.
Premji SK; O'Sullivan CC
Breast Cancer (Auckl); 2024; 18():11782234241234418. PubMed ID: 38410761
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]